



REGIONAL ADULT PARENTERAL DRUG MONOGRAPH

GENERIC NAME
etomidate

Effective Date: Dec 2013	CLASSIFICATION Hypnotic	OTHER NAMES Tomvi®	PAGE 1 of 1
Revised Date: Jan 2024			
Review Date:			

ADMINISTRATION POLICY:

- IV Bolus - **Administration restricted to nurses with training in ED/Cardiac Room/ICU/OR/PACU with direct supervision of a physician**
- IV Infusion - *Not recommended*
- Subcut/IM - *Not recommended*

RECONSTITUTION/DILUTION/ADMINISTRATION:

Available as: 2 mg/mL – 10 mL vials. DO NOT USE product if solution shows haziness, particulate matter, discolouration or leakage.

IV Bolus: Undiluted over 30 to 60 seconds (e.g. for rapid sequence intubation). This drug **MUST** be drawn up in a syringe **JUST PRIOR** to use. Any unused volume to be discarded immediately.

Maximum rate: Over 30 seconds
Maximum concentration: 2 mg/mL

DOSAGE:

Usual: 0.15 – 0.3 mg/kg (Average adult dose = 20 mg) for rapid sequence intubation
 NOTE: Etomidate is recommended for use as a single dose; it is not to be used to maintain sedation after intubation.

STABILITY/COMPATIBILITY:

Compatibility: Compatible with normal saline, D5W, dextrose saline solutions

PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:

- Solution is highly irritating; avoid administration into small vessels; in some cases, pre-administration of lidocaine may be considered.
- Transient skeletal muscle movements, myoclonus (can be minimized by rapidly administering paralytic agent post or pre-medicating with benzodiazepines and opioids)
- Decreased cortisol levels 6 to 8 hours post dose
- Rare cardiovascular events (increases or decreases in blood pressure or heart rate)
- Rare allergic reactions (bronchospasm, anaphylactoid) have been reported
- metroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of products containing propylene glycol. A disulfiram-like reaction may occur.

ADDITIONAL NOTES AND NURSING CONSIDERATIONS:

- Onset of action: 30 to 60 seconds Duration of action: 3 to 5 minutes